(Reuters) - Abbott Laboratories Inc said on Friday that it could have a shorter duration combination therapy for hepatitis C on the market in 2015 with annual sales potential of about $2 billion.
Significantly, its combination therapy does not include tough-to-tolerate interferon, which causes flu-like symptoms that lead many patients with the serious liver disease to stop or delay treatment.
Abbott said that in very small mid-stage trials, a combination of two of its experimental medicines and two other drugs were showing the potential for cure rates as high as 90 percent with as little as 12 weeks of therapy. The shortest duration current patients can hope for is 24 weeks.
（路透社） - 雅培公司上周五表示，它可能在2015年持续时间较短，结合C型肝炎治疗市场上潜在的年销售额约为20亿美元。
发表于 2011-10-23 20:31
